Join us on May 3-5 for SAA's first Global Spondyloarthritis Summit featuring some of the most respected medical professionals, including renowned rheumatologists, a physical therapist, pain management specialist, and others to discuss the latest treatment options and research in spondyloarthritis.
To be a leader in the quest to cure ankylosing spondylitis and related diseases, and to empower those affected to live their lives to the fullest.
Think your pain may be caused by spondylitis? Watch our new awareness video and take the quiz!
Connect with others because no one should have to face spondylitis alone.
The most comprehensive library of spondylitis information and educational materials.
Spondylitis is a relatively unknown disease, but it affects 1 in 100 Americans.
There are many ways to get involved in the community. Which one’s right for you?
Use our state-by-state list of patient recommended and board certified rheumatologists.
View the Directory
Posted February 2019
The purpose of the trial is to study the safety and efficacy of Tildrakizumab in those with psoriatic arthritis (PsA), ankylosing spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA).
Posted March 2018
Posted March 2019
If you’ve been using a drug manufacturer’s copay discount card to help with your out-of-pocket costs for a biologic or other specialty medication, you may soon be in for a surprise. Several large insurance companies and pharmacy benefit managers (PBMs) are implementing new schemes called “copay accumulator programs” that affect how contributions from those same copay cards are applied to your annual out-of-pocket cost requirements.
We offer a wide variety of resources for members of the spondylitis community, physicians and others who are interested in learning more about spondylitis.